Metabolic Reprogramming as Therapy

Note: This page is educational. Fast-moving claims should be checked against current guidelines and primary literature. It does not replace medical advice.

TL;DR

Cancer cells rewire metabolism to support uncontrolled growth: they upregulate glycolysis (the Warburg effect), reroute amino acid and lipid flows, and reshape the local nutrient and pH environment. Therapeutically, metabolic reprogramming flips the question — can we exploit these rewired pathways to selectively starve, sensitize, or kill tumor cells (and reactivate immune attack)?Examples in clinic or trials: IDH1/2 inhibitors (ivosidenib, enasidenib), glutaminase inhibitors, asparaginase (in ALL), arginine deprivation, MAT2A/MTAP synthetic lethality. Most metabolic strategies remain research-stage; resistance via metabolic flexibility is the central challenge. Sources: [1]

---

1. The metabolic backdrop

Hanahan & Weinberg added "deregulating cellular energetics" to the Hallmarks of Cancer in 2011 (Hallmarks). Concrete shifts: Sources: [1]

• Glycolysis upregulation even with O₂ available (Warburg effect) — see Cancer metabolism & Warburg.
• Glutamine addiction — many tumors use glutamine for biosynthesis and TCA-cycle anaplerosis.
• Lipid biosynthesis — fatty-acid synthase upregulation; cholesterol pathway reliance.
• One-carbon metabolism — folate cycle / serine-glycine pathway hijacking; epigenetic effects via SAM.
• Mitochondrial reprogramming — heterogeneous; some tumors are highly OXPHOS-dependent (especially CSCs).
• Microenvironmental acidification (lactate efflux), hypoxia adaptation (HIF-1α stabilization).

These changes drive resistance to chemotherapy and immunotherapy and are themselves treatment vulnerabilities. Sources: [1]

---

2. Approved drugs that exploit metabolic rewiring

Drug / class	Target	Indication
Ivosidenib (AG-120)	mutant IDH1 (R132H)	AML, cholangiocarcinoma
Enasidenib (AG-221)	mutant IDH2	Relapsed/refractory AML
Vorasidenib	mutant IDH1/IDH2	Low-grade glioma (FDA 2024)
Asparaginase	extracellular L-asparagine depletion	ALL (decades-old)
Methotrexate, 5-FU, gemcitabine, pemetrexed	nucleotide / one-carbon metabolism	Many tumors (chemotherapy backbones)
Olaparib + others (PARP inhibitors)	DDR exploiting BRCA1/2-deficient metabolism	BRCA-mut breast/ovarian/prostate/pancreatic

These are real clinical wins where a metabolic vulnerability translated into a drug. Sources: [1]

---

3. Investigational targets

Many programs in Phase I–II:

• Glutaminase inhibitors (CB-839 / telaglenastat) — block glutamine → glutamate → α-KG flow.
• Arginine deprivation (ADI-PEG20) — exploits ASS1-deficient tumors (mesothelioma, melanoma, HCC).
• MAT2A inhibitors / WRN helicase — synthetic lethality with MTAP loss (~15 % of cancers).
• SHMT, MTHFD2, PHGDH inhibitors — one-carbon and serine pathway.
• FASN, ACC, SREBP inhibitors — lipid biosynthesis.
• Mitochondrial inhibitors (IACS-010759, metformin investigational repurposing) — Complex I or oxidative phosphorylation.
• CPI-006, INCB001158 — adenosine/CD73 axis (immuno-metabolic).
• MCT1/4 inhibitors (AZD3965) — block lactate transport.

Many programs have struggled with on-target toxicity (since normal cells share these pathways) and adaptive resistance.

---

4. Tumor metabolism × immunotherapy

A central modern insight: the tumor microenvironment is metabolically hostile to immune cells. Lactate, low pH, hypoxia, and amino-acid scarcity all suppress T-cell function. This makes immunometabolism a hot field: Sources: [1]

• Adenosine pathway (CD73, CD39, A2A receptor) — adenosine in TME suppresses T-cells; antagonists in trials.
• Tryptophan / IDO — IDO inhibitors disappointing in late-stage trials despite preclinical promise.
• Arginine / glutamine — competition between tumor and immune cells.
• Lactate / pH modulation — altering TME to favor T-cell function.

This is a major reason metabolic and immunotherapy strategies are increasingly co-developed.

---

5. Cancer stem cells and metabolism

CSCs (Stem cells & cancer) often have distinct metabolic dependencies from bulk tumor cells — typically more reliant on OXPHOS, fatty-acid oxidation, or specific antioxidant systems. This creates therapeutic openings: drugs that target CSC metabolism (e.g., bedaquiline-class, IACS-010759 in trials) might address the resistance/relapse problem that pure cytotoxics miss.

---

6. Resistance mechanisms

Metabolic plasticity is the field's central problem: Sources: [1]

• Pathway switching — block glycolysis → tumor shifts to OXPHOS, and vice versa.
• Nutrient scavenging — autophagy, macropinocytosis, lipid uptake.
• Microenvironmental adaptation — recruit stromal cells to supply substrates.
• Mitochondrial biogenesis upregulation — to compensate for damage.

Combination strategies blocking parallel metabolic routes are an active research direction.

---

7. What technologists can build

• Flux balance / kinetic models (COBRA, Metabolic Atlas) to predict metabolic vulnerabilities.
• Multi-omics integration with metabolomics (Metabolomics 101) for precision-metabolic targeting.
• MR spectroscopy / hyperpolarized ¹³C MRI analytics for in vivo flux mapping.
• Drug-response models integrating metabolic state.
• Trial enrichment based on metabolic biomarkers (IDH mutation, MTAP loss, ASS1 status).

---

8. Brazilian context

• Brazilian groups in metabolic oncology research: USP, UNICAMP, UFRJ, A.C. Camargo (cell metabolism, CSCs).
• IDH-mutant glioma management (vorasidenib) is being incorporated; access via private oncology and select public referrals.
• Asparaginase remains a backbone of pediatric ALL treatment in SUS through GBOP protocols.

---

See also

• Cancer metabolism & Warburg
• Hallmarks of cancer
• Stem cells & cancer
• Immuno basics & checkpoints
• Metabolomics 101

---

References

1. Liu S, Zhang X, Wang W, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer 2024;23:261. PMID 39574178. https://doi.org/10.1186/s12943-024-02165-x
2. U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
3. American Cancer Society. https://www.cancer.org/cancer.html
4. Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
5. A.C. Camargo Cancer Center. https://accamargo.org.br
6. Fundação do Câncer (Brasil). https://www.cancer.org.br/
7. Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
8. ANVISA. https://www.gov.br/anvisa/pt-br